Skip to content
Optima

Products

Two Products, One Platform

Optima Stroke is clinically validated. Optima Arteria extends the platform across multiple anatomical regions, beginning with radiographs and with MRI at the next stage.

Illustrative image of a clinician reviewing a panoramic dental X-ray

Clinical validation and immediate entry point

Optima Stroke

Optima Stroke is the foundational technology of the portfolio. It automatically detects Carotid Artery Calcification (CAC) in routine panoramic dental X-rays.

  • Validated. The technology was featured in PLOS Digital Health (2023), demonstrating 97% specificity and 87% recall (sensitivity) in identifying high-risk patients.

  • Moving to real-world use. Optima Stroke is progressing from proof of concept to real-world implementation, with advanced discussions under way with healthcare organizations in Israel.

  • Clinical impact. By analyzing radiographs originally collected for dentistry, Optima Stroke can reveal “hidden” stroke risk, supporting clinicians in initiating timely preventive care.

Panoramic dental X-ray shown on a clinic monitor
97%
Specificity
87%
Recall
Man standing for a chest X-ray examination

Multi-market expansion engine

Optima Arteria

Optima Arteria, now in development, is designed to take the platform beyond carotid calcification, with non-contrast lumen and silhouette mapping across multiple anatomical regions, beginning with non-contrast radiographs. A clinical validation study is being prepared, with a fully prepared protocol and an established clinical trial site. The first clinical study is confined to radiographs. Extending the technology to other imaging technologies, including MRI, will follow immediately.

  • Systemic breadth. Starting with the carotid artery, the platform is designed to scale across multiple anatomical regions and vascular and tissue targets.

  • Opportunistic screening. It is intended to enable population-level health assessments from routine orthopedic or chest radiographs, with a broader range of imaging technologies, including MRI, at the next stage.

  • Planned scope. Cardiovascular risk stratification (coronary vessels), abdominal and renal assessment (AAA and RAS identification), peripheral health (PAD screening) and comprehensive “neck-vascular” reports.